- Home
- CSGP vs ALNY Comparison
CSGP vs ALNY Comparison
Compare CSGP & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSGP
- ALNY
- Stock Information
- Founded
- CSGP 1987
- ALNY 2002
- Country
- CSGP United States
- ALNY United States
- Employees
- CSGP N/A
- ALNY N/A
- Industry
- CSGP Business Services
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- CSGP Consumer Discretionary
- ALNY Health Care
- Exchange
- CSGP Nasdaq
- ALNY Nasdaq
- Market Cap
- CSGP 39.2B
- ALNY 42.9B
- IPO Year
- CSGP 1998
- ALNY 2004
- Fundamental
- Price
- CSGP $91.22
- ALNY $454.38
- Analyst Decision
- CSGP Buy
- ALNY Strong Buy
- Analyst Count
- CSGP 12
- ALNY 27
- Target Price
- CSGP $94.00
- ALNY $401.92
- AVG Volume (30 Days)
- CSGP 3.0M
- ALNY 1.4M
- Earning Date
- CSGP 07-22-2025
- ALNY 07-31-2025
- Dividend Yield
- CSGP N/A
- ALNY N/A
- EPS Growth
- CSGP N/A
- ALNY N/A
- EPS
- CSGP 0.25
- ALNY N/A
- Revenue
- CSGP $2,915,500,000.00
- ALNY $2,461,963,000.00
- Revenue This Year
- CSGP $17.24
- ALNY $33.75
- Revenue Next Year
- CSGP $12.81
- ALNY $31.66
- P/E Ratio
- CSGP $359.98
- ALNY N/A
- Revenue Growth
- CSGP 12.18
- ALNY 5.01
- 52 Week Low
- CSGP $68.26
- ALNY $205.87
- 52 Week High
- CSGP $97.43
- ALNY $469.81
- Technical
- Relative Strength Index (RSI)
- CSGP 54.83
- ALNY 75.50
- Support Level
- CSGP $87.49
- ALNY $421.81
- Resistance Level
- CSGP $89.56
- ALNY $445.20
- Average True Range (ATR)
- CSGP 2.28
- ALNY 13.20
- MACD
- CSGP -0.73
- ALNY 0.58
- Stochastic Oscillator
- CSGP 51.71
- ALNY 73.99
About CSGP CoStar Group Inc.
CoStar Group is a leading provider of commercial real estate data and marketplace listing platforms. Its data offering contains in-depth analytical information on over 5 million commercial real estate properties related to various subsectors including office, retail, hotels, multifamily, healthcare, industrial, self-storage, and data centers. It operates many flagship brands such as CoStar Suite, LoopNet, Apartments.com, BizBuySell, and Lands of America, with more than 80% of its revenue classified as subscription-based. The company recently expanded its presence in Canada, the United Kingdom, Spain, and France.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.